Sunday
09.15.2019
10:09 PM
Login form
Search
Calendar
Entries archive

My site

Main » 2019 » March » 30

Inaugural Award will be Presented to SpaceIL upon a Successful Lunar Landing 

LOS ANGELES -Friday 29 March 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- XPRIZE, the global leader in designing and operating world-changing incentive competitions, announces that it will offer a $1 million Moonshot Award in recognition of an XPRIZE team demonstrating the achievement of a “moonshot” technological feat outside the parameters or timeframe of an XPRIZE competition.

The Award is inspired by SpaceIL, a former Google Lunar XPRIZE team, whose mission to become the first private, non-government entity to land on the surface of the Moon is underway, with an anticipated landing on April 11, 2019. A successful lunar landing will result in SpaceIL receiving the inaugural Moonshot Award from XPRIZE.

“Though the Google Lunar XPRIZE went unclaimed, we are thrilled to have stimulated a diversity of teams from around the world to pursue their ambitious lunar ... Read more »

Views: 19 | Added by: africa-live | Date: 03.30.2019 | Comments (0)

Velodyne is the Lidar Industry Leader in Mass Production

 

SAN JOSE, Calif.-Friday 29 March 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Velodyne has shipped a cumulative total of 30,000 lidar sensors with a total value of half a billion dollars. This achievement underscores Velodyne&rsquo ... Read more »

Views: 37 | Added by: africanewsline | Date: 03.30.2019 | Comments (0)

SUMMIT, N.J. -Friday 29 March 2019 [ AETOS Wire ]

The CHMP adopted two positive opinions recommending European Commission approval of:

    REVLIMID in combination with bortezomib and dexamethasone (RVd) in adult patients with previously untreated multiple myeloma who are not eligible for transplant
    IMNOVID in combination with bortezomib and dexamethasone (PVd), for adult patients with multiple myeloma, who have received at least one prior treatment regimen including lenalidomide

(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for two triplet regimens based on Celgene’s proprietary IMiD® medications, REVLIMID (lenalidomide) and IMNOVID (pomalidomide).

The CHMP recommended approval of an expanded indication of REVLIMID as combination therapy with bortezomib and dex ... Read more »

Views: 22 | Added by: africa-live | Date: 03.30.2019 | Comments (0)

PARIS LA DÉFENSE -Friday 29 March 2019 [ AETOS Wire ]

    85.58% of Gemalto shares have been tendered to the Offer
    All Offer Conditions are now satisfied or waived, making the Offer unconditional
    Settlement of tendered Shares will take place on 2 April 2019
    Remaining Shares can be tendered during the Post-Closing Acceptance Period which will start on Monday 1 April 2019 and end on Monday 15 April 2019
    Gemalto will be consolidated as of 1 April 2019 in Thales’s financial statements

(BUSINESS WIRE)-- Regulatory News:

Reference is made to the joint press release by Thales (Euronext Paris: HO) and Gemalto (Euronext Amsterdam and Paris: GTO) dated 27 March 2018 in relation to the launch of the recommended all-cash offer by Thales for all the issued and outstanding shares of Gemalto (the Offer), the publication of the Offer Document, and the join ... Read more »

Views: 23 | Added by: africa-live | Date: 03.30.2019 | Comments (0)